<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143791</url>
  </required_header>
  <id_info>
    <org_study_id>NM-13-038-ID-SC</org_study_id>
    <nct_id>NCT02143791</nct_id>
  </id_info>
  <brief_title>A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.</brief_title>
  <acronym>Prodigy-I</acronym>
  <official_title>A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM
      neuromodulation system in the management of failed back surgery syndrome or chronic
      intractable pain of the trunk and/or limbs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary endpoint is the percentage of pain relief at the 3-month visit compared to baseline visit, as measured by the Visual Analog Scale (VAS).</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse events (SAEs) and/or procedure/device-related adverse events ((S)ADEs)</measure>
    <time_frame>from enrollment to 12 months follow up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Burst stimulation</arm_group_label>
    <description>At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Burst stimulation</intervention_name>
    <arm_group_label>Burst stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prodigy system</intervention_name>
    <arm_group_label>Burst stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are indicated for Spinal Cord Stimulation (SCS) and with Failed Back Surgery
        Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with chronic, intractable pain of the trunk and/or limbs, including
             unilateral or bilateral pain associated with the following: failed back surgery
             syndrome or intractable low back and/or leg pain

          -  Patient is considered by the investigator as a candidate for implantation of a SCS
             system

          -  Patient is â‰¥ 18 years of age

          -  Patient must be willing and able to comply with study requirements

          -  Patient must indicate his/her understanding of the study and willingness to
             participate by signing an appropriate Informed Consent Form

        Exclusion Criteria:

          -  Patient is immune-compromised

          -  Patient has history of cancer requiring active treatment in the last 6 months

          -  Patient has a documented history of substance abuse (narcotics, alcohol, etc.) or
             substance dependency in the last 6 months

          -  Patients with a SCS system or implantable infusion pump implanted previously

          -  Patient has a life expectancy of less than one year

          -  Patient is pregnant or is planning to become pregnant during the duration of the
             investigation

          -  Patient is unable to comply with the follow up schedule

          -  Patient needing legally authorized representative

          -  Patient unable to read and write

          -  Patient is currently participating in another clinical investigation with an active
             treatment arm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Van Havenbergh</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Augustinus, Wilrijk, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roni Diaz</last_name>
    <role>Study Director</role>
    <affiliation>St. Jude Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roni Diaz</last_name>
    <phone>+1 972 309 8601</phone>
    <email>rdiaz@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique Van Bree</last_name>
    <phone>+3227746947</phone>
    <email>mvanbree@sjm.com</email>
  </overall_contact_backup>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCS</keyword>
  <keyword>Burst stimulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Intractable</mesh_term>
    <mesh_term>Failed Back Surgery Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
